PPP Portfolio Management Strategies Meeting September 15, 2004

1

Stop TB Partnership Working Group on New
Drugs
2
Stop TB Partnership
DOTS Expansion
New TB Vaccines
Advocacy Communications
TB/HIV
New TB Diagnostics
DOTS-Plus MDR -TB
New TB Drugs
Treatment Today
Treatment Tomorrow
3
Working Group Mission

• To facilitate and foster global collaborations
  for the development of new effective and
  affordable anti-TB drugs.

4
Vision
VISION
5
New Drug Profile

• Shorten TB treatment to lt2 months
• Novel mechanism of action (MDR/XDR-TB)
• No drug-drug interactions with ARVs
• Orally available
• Once daily or intermittent therapy
• Low cost of goods

6
STOP TB PARTNERSHIP ASSESSMENT OF GLOBAL PORTFOLIO
7
TB Alliance Portfolio
Contracted Program
Program in discussion
Discovery
Preclinical
Clinical Testing
Compounds, Analogs and Derivatives
Moxifloxacin (Bayer)
Nitroimidazole OPC-77073 (Otsuka)
Multi-Functional Molecules (Cumbre)
Nitroimidazole Analogs (University of
Auckland/University of Chicago)
Nitroimidazole PA-824 (Chiron/Novartis)
Quinolones (KRICT/Yonsei University)
Nitroimidazole OPC-67683 (Otsuka)
Bacterial Topoisomerase Inhibitors (GlaxoSmithKlin
e)
InhA Inhibitors (GlaxoSmithKline)
Pleuromutilins (GlaxoSmithKline)
Focused Screening 2 Projects (GlaxoSmithKline)
Riminophenazines (Institute of Materia
Medica/BTTTRI)
Malate Synthase Inhibitors (GlaxoSmithKline/Rockef
eller University/Texas AM)
New Targets (University of Pennsylvania)
Protease Inhibitors Queen Mary College
Proteasome Inhibitors (Cornell University)
Protein Synthesis Inhibitor (Pharma)
Screening and Target Identification (AstraZeneca)